Joshua Barton

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

Bruce Cree, Gary Cutter, Jerry S. Wolinsky et al. · The Lancet Neurology · 2020 · 104 citations · Full text

Life Sciences, Neurology, Neuroscience +9

Differing Structural and Functional Patterns of Optic Nerve Damage in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder

Ting Shen, Yuyi You, Sukanya Arunachalam et al. · Ophthalmology · 2018 · 76 citations · Full text

Medicine, Neurology, Neuroscience +17

Evidence of progressive tissue loss in the core of chronic MS lesions: A longitudinal DTI study

Alexander Klistorner, Chenyu Wang, Con Yiannikas et al. · NeuroImage Clinical · 2017 · 63 citations · Full text

Medicine, Neurology, Radiology +17

Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G–Positive Neuromyelitis Optica Spectrum Disorder

Yuyi You, Ling Zhu, Ting Zhang et al. · Ophthalmology · 2019 · 60 citations · Full text

Medicine, Neurology, Ophthalmology +17

Expansion of chronic lesions is linked to disease progression in relapsing–remitting multiple sclerosis patients

Samuel Klistorner, Michael Barnett, Con Yiannikas et al. · Multiple Sclerosis Journal · 2020 · 52 citations

Life Sciences, Neurology, Neuroscience +17